Relapses linked to accelerated disability progression in SPMS

Relapses linked to accelerated disability progression in SPMS

(HealthDay)—For patients with secondary progressive multiple sclerosis (SPMS), relapses are associated with accelerated disability progression, according to a study published online July 27 in JAMA Neurology.

Nathaniel Lizak, M.B.B.S., from the University of Melbourne in Australia, and colleagues examined the association between relapses and rate of disability accumulation in with SPMS in an observational cohort study. Patient data were collected prospectively from the MSBase international registry; 4,997 patients with SPMS were identified and 1,621 were included in the study.

The researchers found that 40.8 percent of the patients experienced superimposed relapses during SPMS. There was no association noted for receipt of therapy and relapses during early relapsing-remitting MS with disability accumulation during the second progressive phase. During the secondary progressive disease stage, higher relapse rates were associated with an for becoming wheelchair-dependent (hazard ratio, 1.87). Greater receipt of disease-modifying therapies was significantly associated with a reduced rate of disability progression and for being wheelchair-dependent among patients who experienced superimposed relapses during SPMS.

"Although early active treatment during relapsing remitting MS is associated with a delay in the onset of SPMS, the rate of disability accumulation once the secondary progressive phase has commenced is not substantially modified by early treatment decisions," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)

Journal information: Archives of Neurology

Copyright © 2020 HealthDay. All rights reserved.

Citation: Relapses linked to accelerated disability progression in SPMS (2020, July 29) retrieved 25 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Rituximab beneficial in secondary progressive MS


Feedback to editors